INTAKING AN ANTIVIRAL BY INHALATION OR SPRAYING FOR RESPIRATORY TRACT INFECTION

Abstract

Methods of treatment to inhibit or kill microorganisms (Bacteria or Virus) from infecting a respiratory tract of a human patient and to treat the respiratory tract when already infected by the microorganism are described. The method of treatment may include the step of administering a therapeutically effective dose of a treatment medication comprising eugenol to the patient via a nasal passageway into a respiratory system of the patient. Eugenol is found in clove oil, cinnamon oil, and other essential oils. Any one or more of these eugenol-containing oils may be used.

Claims

1. A method, comprising: administering an antiviral treatment by inhalation to kill viruses infecting a respiratory tract of a human patient, comprising: administering a therapeutically effective dose of a treatment medication in a nasal passageway of the human patient to or kill the viruses, the treatment medication comprising eugenol as an active ingredient such that as the human patient breathes, the eugenol is drawn via a nasal passageway into the respiratory tract of the human patient, wherein the eugenol is an active ingredient wherein a source of the eugenol as the active ingredient is either cinnamon oil or clove oil or a mixture of the cinnamon oil and the clove oil, and wherein the treatment medication comprises at least 20% v/v concentration.

2.-4. (canceled)

5. The method of claim 1, wherein the step of administering the treatment medication comprising the eugenol comprises administering a combination of any two or more of the clove oil, the cinnamon oil, and other essential oils.

6. (canceled)

7. The method of claim 1, wherein the step of administering the treatment medication comprises administering menthol.

8. The method of claim 1, wherein the step of administering the therapeutically effective dose includes providing the therapeutically effective dose via inhalation after spraying the treatment medication into the nasal passageway of the human patient.

9. The method of claim 1, wherein the step of administering the therapeutically effective dose comprises leading a tube from a container of the treatment medication into the nasal passageway of the human patient such that inhalation by the human patient draws the treatment medication from the tube of the container into the respiratory tract of the human patient.

10. (canceled)

11. The method of claim 1, wherein the step of administering the therapeutically effective dose includes administering the therapeutically effective dose when the human patient is already infected by a virus of the viruses.

12. The method of claim 1, wherein the step of administering the therapeutically effective dose includes administering the therapeutically effective dose continuously or at prescribed intervals for inhalation via the nasal passageway to reach the respiratory tract, wherein the treatment medication dwells in the respiratory tract and acts as an anti-viral medication.

13. A method, comprising: administering a continuous method of treatment of a respiratory tract of a human patient to kill viruses, the continuous method of the treatment comprising: administering a therapeutically effective dose of a treatment medication comprising eugenol to the human patient by depositing the therapeutically effective dose into a nasal passageway, such that the therapeutically effective dose is drawn into a respiratory tract of the human patient in order to kill the viruses, wherein the depositing is by using inhalation or spraying by the human patient during breathing to draw the treatment medication into the respiratory tract, wherein the eugenol is an active ingredient, wherein a source of the eugenol as the active ingredient is either cinnamon oil or clove oil or a mixture of the cinnamon oil and the clove oil, and wherein the treatment medication comprises at least 20% v/v concentration.

14. The method of claim 13, wherein the treatment medication dwells in the respiratory tract and acts as an anti-viral medication.

15-20. (canceled)

Description

DETAILED DESCRIPTION

[0024] The present technology presents a treatment method and treatment medication that can be used either as (1) a curative treatment for persons infected in respiratory tract with a virus or bacteria, or (2) as a prophylactic treatment to prevent a bacterial or viral infection, or both.

[0025] The treatment medication that includes eugenol kills or inhibits microorganisms residing in the nasal cavity and the trachea, thereby inhibiting infection of the lungs. The delivered treatment medication, upon reaching the lungs, also facilitates killing or inhibiting microorganisms already in the lungs.

[0026] The treatment medication includes a natural oil that has eugenol as a component. For example, and without limitation, clove oil and cinnamon oil each comprise eugenol. Eugenol is an allyl chain-substituted guaiacol, a member of the allylbenzene class of chemical compounds. It is a colorless to pale yellow, aromatic oily liquid extracted from certain essential oils, especially from dove oil, cinnamon and some essential oils. Accordingly, embodiments of the treatment medication may include any one or more of these essential oils. Eugenol is present in high concentrations in clove oil. Eugenol has a pleasant, spicy, clove-like scent. The name eugenol is derived from Eugenia carophyllata, the former Linnean nomenclature term for cloves, (The currently accepted name is Syzygium aromaticum.)

[0027] According to exemplary embodiments, clove oil can be used alone as the treatment medication as antivirus. In other exemplary embodiments it may be used together with cinnamon oil as the treatment medication as antivirus. In exemplary methods of administration, the treatment medication may be administered via the nasal passageway and thereby into the respiratory tract. This mode of administration, in therapeutically effective amount, prevents respiratory tract infection (i.e., inhibits infection) through inhalation of the microorganism (herein defined to include both viruses and bacteria) that adversely affects the respiratory tract, For example, the microorganism that attacks the respiratory tract may include, but is not limited to, a virus such as a coronavirus (exemplified by colds, influenza, and covid-19 viruses) or any other virus or bacterium that primarily affects the respiratory tract.

[0028] In an exemplary embodiment, the daily dose of eugenol to be supplied to the patient for daily therapeutic effectiveness is to use a conventional nasal spray squeeze bottle and to deliver two sprays in each nostril every four hours for 24 hours only. For prevention, deliver one spray in each nostril three times a day. The dose may be diluted with any suitable diluent, to a 20% v/v concentration. The dose may be delivered continuously, or in partial doses at selected periodic intervals, for example hourly or every three hours, etc. For example, in the event of a protocol of periodic dosing, of the daily dose is delivered n times per day, where n can vary as a practical matter, from about 3 to about 24. It should be noted that clove oil and cinnamon oil are available at a range of concentrations of eugenol, which is the active ingredient. As a consequence, the therapeutic dose is based on eugenol quantity which can be calculated based on the concentration of eugenol in the clove oil or cinnamon oil, or other oils disclosed herein.

[0029] In an exemplary embodiment, administration of the treatment medication into the nasal passageway may be carried out continuously using the inhalation of the patient to draw the treatment medication from the nasal cavity through the nasal passageway and thence to the lungs. In this exemplary embodiment, the daily dose of medication is administered continuously and the rate of treatment medication entering the nasal passageway is controlled to correspond to the required dose. This controlled continuous dosage may he effectuated by control of the concentration of the treatment medication being inhaled, for example, or by flow control of the quantity of treatment medication flowing, or both. The method is advantageous and can be practiced by several techniques. For example, by use of a device like a nasal cannula that has the end of the delivery tube in an upper section of a bottle containing the treatment medication, where vapor from the treatment medication accumulates. Thus, during normal breathing, upon inhalation, vapor is drawn into the tube to the cannula and into the nasal passageway to the lungs. Of course, other techniques may also be used to provide a continuous supply of treatment m edication.

[0030] As indicated above, in some exemplary embodiments, the treatment medication may be provided by a spray bottle. Alternatively, bottles equipped with metering pumps, that control the dose, such as the dose-control led pump bottles that are commonly used for nasalallergy sprays, may also be used.

[0031] In another exemplary embodiment, diluents and additives that are not harmful or toxic to the respiratory tract may be added to the treatment medication. Additives such as (but not limited to) menthol may further aid the patient by facilitating or easing the act of breathing.

[0032] A further embodimentprovides adding the treatment medication that includes eugenol to a patch for transdermal delivery of the eugenol, in a continuous manner. In this instance additive may be added to facilitate the transdermal application of the eugenol. The eugenol may be derived from natural sources.

[0033] The foregoing description provides details of the inventive technology and presents exemplary embodiments. The description does not limit the scope of the inventive technology which is only limited by the scope of the appended patent claims as interpreted by a court of competent jurisdiction.